Login to Your Account



Clinic Roundup


Monday, June 6, 2011
• Cytokinetics Inc., of South San Francisco, Calif., completed a Phase IIa trial of its skeletal muscle activator, CK-2017357, in peripheral artery disease. The trial showed that CK-2017357 increased calf muscle performance in patients with calf muscle claudication associated with peripheral artery disease. Increasing calf muscle performance and adverse events were both related to increasing dose and plasma concentration of the drug. The company presented those results in a poster at the 22nd Annual Sessions of the Society for Vascular Medicine, June 2-4, Boston, Mass.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription